Compare CSGS & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSGS | STOK |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 1996 | 2019 |
| Metric | CSGS | STOK |
|---|---|---|
| Price | $79.85 | $30.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $72.96 | $34.50 |
| AVG Volume (30 Days) | 481.9K | ★ 707.9K |
| Earning Date | 02-03-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 29.70 | N/A |
| EPS | ★ 2.95 | 0.68 |
| Revenue | ★ $1,216,848,000.00 | $205,632,000.00 |
| Revenue This Year | $2.90 | $430.24 |
| Revenue Next Year | $4.71 | N/A |
| P/E Ratio | ★ $27.05 | $43.08 |
| Revenue Growth | 3.31 | ★ 1128.17 |
| 52 Week Low | $52.94 | $5.35 |
| 52 Week High | $79.88 | $38.69 |
| Indicator | CSGS | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 76.87 | 45.95 |
| Support Level | $79.40 | $27.01 |
| Resistance Level | $79.69 | $31.70 |
| Average True Range (ATR) | 0.30 | 2.17 |
| MACD | 0.08 | -0.42 |
| Stochastic Oscillator | 87.67 | 39.65 |
CSG Systems International Inc is a purpose-driven, SaaS platform company that enables companies in a wide variety of industry verticals to tackle the growing complexity of business in the digital age. The company's cloud-first architecture and customer-centric approach empower companies to deliver unforgettable experiences for B2B (business-to-business), B2C (business-to-consumer), and B2B2X (business-to-business-to-consumer) customers, making it easier for people and businesses to connect to, use and pay for the services the company offers. The company operates in one segment i.e. Solutions and Services. Geographically, the company generates revenue from the United States.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.